Advances in Aurora kinase inhibitor patents

Bibliography

• Cancer: Key facts. July 2008. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html [Accessed 1 August 2008]
   Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4(12):927-36
   PubMed Web of Science ®Google Scholar
• Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786(1):60-72
   PubMed Web of Science ®Google Scholar
• Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14(6):1639-48
   PubMed Web of Science ®Google Scholar
• Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5(1):1-10
   PubMed Web of Science ®Google Scholar
• Agnese V, Bazan V, Fiorentino FP, et al. The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 2007;18(Suppl 6):vi47-52
   PubMed Web of Science ®Google Scholar
• Girdler F, Gascoigne KE, Eyers PA, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006;119(Pt 17):3664-75
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008;610:54-73
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 2008;12(1):69-80
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Bearss DJ, Vankayalapati H. Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents 2003;3(1):25-34
   PubMedGoogle Scholar
• Mortlock AA, Keen NJ, Jung FH, et al. Progress in the development of selective inhibitors of aurora kinases. Curr Top Med Chem 2005;5(8):807-21
   PubMed Web of Science ®Google Scholar
• Matthews N, Visintin C, Hartzoulakis B, et al. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther 2006;6(1):109-20
   PubMed Web of Science ®Google Scholar
• Vertex Pharma Inc. US7361492; 2008
   Google Scholar
• Vertex Pharma Inc. WO03092607A2; 2004
   Google Scholar
• Vertex Pharma Inc. WO04000833A1; 2003
   Google Scholar
• Wang Y, Serradell N. VX-680/MK-0457. Drugs Future 2007;32(2):144-7
   Google Scholar
• Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007;251(2):323-9
   PubMed Web of Science ®Google Scholar
• Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66(2):1007-14
   PubMed Web of Science ®Google Scholar
• Vertex Pharma Inc. WO07056163A2; 2007
   Google Scholar
• Vertex Pharma Inc. WO07056164A2; 2007
   Google Scholar
• Vertex Pharma Inc. WO07056221A2; 2007
   Google Scholar
• Vertex Pharma Inc. WO07059299A1; 2007
   Google Scholar
• Vertex Pharma Inc. WO07022384A2; 2007
   Google Scholar
• AstraZeneca AB. US7214518; 2002
   Google Scholar
• AstraZeneca AB. WO03055491A1; 2002
   Google Scholar
• AstraZeneca AB. US20050070561A1; 2002
   Google Scholar
• AstraZeneca AB. WO04058781A1; 2004
   Google Scholar
• AstraZeneca AB. WO04094410A1; 2004
   Google Scholar
• AstraZeneca AB. WO04105764A1; 2004
   Google Scholar
• AstraZeneca AB. WO04058752A1; 2004
   Google Scholar
• AstraZeneca AB. WO04113324A1; 2004
   Google Scholar
• AstraZeneca AB. WO06129064A1; 2006
   Google Scholar
• AstraZeneca AB. WO07083096A2; 2007
   Google Scholar
• Heron NM, Anderson M, Blowers DP, et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett 2006;16(5):1320-3
   PubMed Web of Science ®Google Scholar
• Jung FH, Pasquet G, Lambert-Van der Brempt C, et al. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 2006;49(3):955-70
   PubMed Web of Science ®Google Scholar
• Mortlock AA, Foote KM, Heron NM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50(9):2213-24
   PubMed Web of Science ®Google Scholar
• Pfizer Italia S.R.L. US7141568; 2006
   Google Scholar
• Fancelli D, Berta D, Bindi S, et al. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem 2005;48(8):3080-4
   PubMed Web of Science ®Google Scholar
• Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49(24):7247-51
   PubMed Web of Science ®Google Scholar
• Pharmacia Italia S.P.A. WO04007504A1; 2004
   Google Scholar
• Pharmacia Italia S.P.A. WO05074922A1; 2005
   Google Scholar
• Nerviano Medical Sciences S.R.L. WO07009898A1; 2007
   Google Scholar
• Nerviano Medical Sciences S.R.L. WO07138017A1; 2007
   Google Scholar
• Millennium Pharmaceuticals Inc. WO05111039A2; 2005
   Google Scholar
• Millennium Pharmaceuticals Inc. WO08063525A1; 2008
   Google Scholar
• Sells T, Ecsedy JA, Stroud SG, et al. MLN8237: an Orally Active Small Molecule Inhibitor of Aurora A kinase in Phase I clinical trials. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
   Google Scholar
• Millennium Pharmaceuticals Inc. WO08021038A2; 2008
   Google Scholar
• Millennium Pharmaceuticals Inc. WO06041773A2; 2006
   Google Scholar
• Cyclacel Ltd. WO04043953A1; 2004
   Google Scholar
• Cyclacel Ltd. WO05012298A1; 2004
   Google Scholar
• Cyclacel Ltd. WO05075468A2; 2005
   Google Scholar
• Cyclacel Ltd. WO06075152A1; 2006
   Google Scholar
• Cyclacel Ltd. WO07042786A2; 2007
   Google Scholar
• Cyclacel Ltd. WO07042784A2; 2007
   Google Scholar
• Griffiths G, Scaerou F, Sorrell D, et al. Anti-tumor activity of CYC116, a novel small molecule inhibition of Aurora kinases and VEGFR2. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
   Google Scholar
• Sunesis Pharmaceuticals Inc. WO06036266A1; 2006
   Google Scholar
• Sunesis Pharmaceuticals Inc. WO07013964A1; 2007
   Google Scholar
• Oslob JD, Romanowski MJ, Allen DA, et al. Discovery of a potent and selective Aurora kinase inhibitor. Bioorg Med Chem Lett 2008;18(17):4880-4
   PubMed Web of Science ®Google Scholar
• Gamo K, Belmont B, Tangonan B, et al. SNS-314, a novel small-molecule Aurora kinase inhibitor, induces cell-cycle defects and potently supresses tumor growth. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
   Google Scholar
• Smithkline Beecham Co. US7282588; 2007
   Google Scholar
• Yang J, Anderson K, Hardwicke MA, et al. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B kinase with extremely AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
   Google Scholar
• Smithkline Beecham Co. WO07018941A2; 2007
   Google Scholar
• Smithkline Beecham Co. WO07024843A2; 2007
   Google Scholar
• Smithkline Beecham Co. WO04112719A2; 2004
   Google Scholar
• Pfizer Products Inc. WO06067614A2; 2006
   Google Scholar
• Pfizer Products Inc. WO07072158A2; 2007
   Google Scholar
• Bhattacharya S, Wishka D, Luzzio M, et al. SAR and chemistry of Aurora kinase inhibitors: Discovery of PF-3814735, an oral clinical candidate. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
   Google Scholar
• University of Arizona and Montigen Pharmaceuticals Inc. US7312226; 2007
   Google Scholar
• University of Arizona and Supergen Inc. US7326712; 2008
   Google Scholar
• University of Arizona and Supergen Inc. US7326713; 2008
   Google Scholar
• University of Arizona and Supergen Inc. US7335662; 2008
   Google Scholar
• Warner SL, Bashyam S, Vankayalapati H, et al. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 2006;5(7):1764-73
   PubMed Web of Science ®Google Scholar
• Supergen Inc. WO06116733A2; 2006
   Google Scholar
• Supergen Inc. WO08055233A1; 2008
   Google Scholar
• Miikana Therapeutics Inc. WO06055831A2; 2006
   Google Scholar
• Miikana Therapeutics Inc. WO07041358A2; 2007
   Google Scholar
• Bray MR. ENMD-981693: An oral, aurora kinase – angiogenesis inhibitor. Drug Discovery and Development of Innovative Therapeutics (Meeting Abstracts); 2007 August 6-9; Boston, MA; 2007
   Google Scholar
• Bray MR. ENMD-2076, an oral Aurora A and angiogenesis kinase inhibitor. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
   Google Scholar
• Astex Technology Ltd. WO05002552A2; 2005
   Google Scholar
• Astex Technology Ltd. WO06003440A1; 2006
   Google Scholar
• Astex Technology Ltd. WO06070195A1; 2006
   Google Scholar
• Astex Technology Ltd. WO06070198A1; 2006
   Google Scholar
• Astex Technology Ltd. WO06070202A1; 2006
   Google Scholar
• Astex Technology Ltd. WO07077435A1; 2007
   Google Scholar
• Astex Technology Ltd. WO08001101A2; 2008
   Google Scholar
• Astex Technology Ltd. WO08001115A2; 2008
   Google Scholar
• Astex Technology Ltd. WO06070192A1; 2006
   Google Scholar
• Rigel Pharmaceuticals Inc. WO05118544A2; 2005
   Google Scholar
• Rigel Pharmaceuticals Inc. WO06055561A2; 2006
   Google Scholar
• Chroma Therapeutics Ltd. WO06117552A1; 2006
   Google Scholar
• Chroma Therapeutics Ltd. WO06117570A1; 2006
   Google Scholar
• Chroma Therapeutics Ltd. WO07072017A2; 2007
   Google Scholar
• Chan F, Sun C, Perumal M, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007;6(12 Pt 1):3147-57
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Sun C, Bouloc N, et al. Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. Bioorg Med Chem Lett 2007;17(23):6567-71
   Google Scholar
• Boehringer Ingelheim Pharma KG. US6638965; 2003
   Google Scholar
• Boehringer Ingelheim International GMBH. WO07122219A1; 2007
   Google Scholar
• Boehringer Ingelheim International GMBH. US20070032514A1; 2007
   Google Scholar
• Boehringer Ingelheim International GMBH. WO07115999A1; 2007
   Google Scholar
• Ortho McNeil Pharmaceutical Inc. US6924302; 2001
   Google Scholar
• Janssen Pharmaceutica N.V. WO06042215A1; 2006
   Google Scholar
• Lin R, Connolly PJ, Huang S, et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem 2005;48(13):4208-11
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica N.V. WO06050076A1; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. WO06074984A1; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. WO06074985A1; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. WWO07047646A2; 2007
   Google Scholar
• Hughes TV, Emanuel SL, O'Grady HR, et al. 7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity. Bioorg Med Chem Lett 2008;18(18):5130-3
   Google Scholar
• Hoff Hoffmann-La Roche Inc. US7285569; 2007
   Google Scholar
• F Hoffmann-La Roche AG. WO06108489A1; 2006
   Google Scholar
• F Hoffmann-La Roche AG. WO07068465A1; 2007
   Google Scholar
• F Hoffmann-La Roche AG. WO06063841A2; 2006
   Google Scholar
• F Hoffmann-La Roche AG. WO07107346A1; 2007
   Google Scholar
• F Hoffmann-La Roche AG. WO06108488A1; 2006
   Google Scholar
• F Hoffmann-La Roche AG. WO08022747A1; 2008
   Google Scholar
• F Hoffmann-La Roche AG. WO06133885A1; 2006
   Google Scholar
• Genentech Inc and Hoffman La Roche Inc. WO07022102A2; 2007
   Google Scholar
• Genentech Inc. WO07120333A2; 2007
   Google Scholar
• Rawson TE, Ruth M, Blackwood E, et al. A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. J Med Chem 2008;51(15):4465-75
   PubMed Web of Science ®Google Scholar
• Hoffman-La Roche Inc. US7226923; 2007
   Google Scholar
• F Hoffmann-La Roche AG. WO07107298A1; 2007
   Google Scholar
• F Hoffmann-La Roche AG. WO08017465A1; 2008
   Google Scholar
• Genentech Inc. WO07120339A1; 2007
   Google Scholar
• Genentech Inc. WO08079719A1; 2008
   Google Scholar
• Bristol-Myers Squibb Company. US20070004731A1; 2007
   Google Scholar
• Bristol-Myers Squibb Company. US7232901; 2007
   Google Scholar
• Bristol-Myers Squibb Company. US7402582; 2008
   Google Scholar
• Bristol-Myers Squibb Company. US7405213; 2008
   Google Scholar
• Bristol-Myers Squibb Company. WO07005630A1; 2007
   Google Scholar
• Bristol-Myers Squibb Company. WO08083398A2; 2008
   Google Scholar
• Bristol-Myers Squibb Company. WO08086264A1; 2008
   Google Scholar
• Takeda San Diego Inc. WO06023931A2; 2006
   Google Scholar
• Takeda San Diego Inc. WO06044687A2; 2006
   Google Scholar
• Takeda San Diego Inc. WO07117995A2; 2007
   Google Scholar
• Takeda San Diego Inc. WO07044779A1; 2007
   Google Scholar
• Takeda San Diego Inc. WO08045834A2; 2008
   Google Scholar
• Bayer Pharmaceuticals Co. WO07064932A2; 2007
   Google Scholar
• Schering Co. WO08057512A2; 2008
   Google Scholar
• Schering AG. US20070191393A1; 2007
   Google Scholar
• Bayer Schering Pharma AG. US20080058358A1; 2008
   Google Scholar
• Bayer Schering Pharma AG. US20080167330A1; 2008
   Google Scholar
• Mitsubishi Tanabe Pharma Co. WO06118231A1; 2006
   Google Scholar
• Mitsubishi Tanabe Pharma Co. WO08053812A1; 2008
   Google Scholar
• Mitsubishi Pharma Co. WO05113550A1; 2005
   Google Scholar
• Banyu Pharmaceutical Co Ltd. US20080027042A1; 2008
   Google Scholar
• Banyu Pharmaceutical Co Ltd. WO08026768A1; 2008
   Google Scholar
• Amgen Inc. WO05113494A2; 2005
   Google Scholar
• Amgen Inc. WO07100646A1; 2007
   Google Scholar
• Amgen Inc. WO07087276A1; 2007
   Google Scholar
• Amgen Inc. WO08057280A1; 2008
   Google Scholar
• European Molecular Biology Laboratory (EMBL). WO05040368A2; 2005
   Google Scholar
• European Molecular Biology Laboratory (EMBL). WO07113005A2; 2007
   Google Scholar
• European Molecular Biology Laboratory (EMBL). WO07115805A2; 2007
   Google Scholar
• IRM LLC WO07016228A2; 2007
   Google Scholar
• Andersen CB, Wan Y, Chang JW, et al. Discovery of selective aminothiazole aurora kinase inhibitors. ACS Chem Biol 2008;3(3):180-92
   Google Scholar
• CrystalGenomics Inc. WO07073117A1; 2007
   Google Scholar
• CrystalGenomics Inc. WO07083978A1; 2007
   Google Scholar
• Aventis Pharma S.A. WO07012972A2; 2007
   Google Scholar
• Biogen Idec Inc. WO08094602A2; 2008
   Google Scholar
• Nissan Chemical Industries Ltd. WO08001883A1; 2008
   Google Scholar
• Praecis Pharmaceuticals Inc. WO08016547A2; 2008
   Google Scholar
• TransTech Pharma Inc. WO07095124A2; 2007
   Google Scholar
• TranstechPharma. Available from: http://www.ttpharma.com/pipeline_kinase.html [Cited 27th Sept 2008]
   Google Scholar
• Coumar MS, Wu JS, Leou JS, et al. Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold. Bioorg Med Chem Lett 2008;18(5):1623-7
   Google Scholar
• Deng XQ, Wang HY, Zhao YL, et al. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors. Chem Biol Drug Des 2008;71(6):533-9
   PubMed Web of Science ®Google Scholar
• Coumar MS, Leou JS, Shukla P, et al. Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity. J Med Chem (Under Revision); 2008
   Google Scholar
• Emanuel S, Rugg CA, Gruninger RH, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65(19):9038-46
   PubMed Web of Science ®Google Scholar
• Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem 2007;50(17):4027-37
   PubMed Web of Science ®Google Scholar